The overall goal of this initiative is to strengthen the research infrastructure for cancer research at Florida A&M University through research collaboration in a focused and coordinated effort. Despite significant discovery of chemotherapeutic agents and their mechanisms of action, the need for new chemical entities having new mechanisms of action for the treatment of breast and lung cancer remains high. Therefore, an aggressive exploitation of new anticancer agents/combination and their molecular mechanisms involved in tumor regression are planned through research collaboration. Breast and lung cancer are the most common cancer affecting minority populations and these two cancers hence been chosen to be pursued at FAMU. Furthermore, FAMU has researchers who are performing cutting edge research in these areas and hence can contribute in building a strong infrastructure for other researchers. Another impetus for this activity is to take a step towards remedy for the persistent disparity in the number of minority investigators involved in targeted cancer therapy research. The difficulty in implementing innovative approaches in cancer research at historically black colleges and universities is due to the lack of adequate resources, trained investigators and research infrastructure for breast and lung cancer therapy.

National Institute of Health (NIH)
National Institute on Minority Health and Health Disparities (NIMHD)
Exploratory Grants (P20)
Project #
Application #
Study Section
Special Emphasis Panel (ZMD1-RN (01))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Florida Agricultural and Mechanical University
United States
Zip Code
Odewumi, Caroline O; Fils-Aime, Shiela; Badisa, Veera L D et al. (2015) Chemoprotective effect of monoisoamyl 2, 3-dimercaptosuccinate (MiADMS) on cytokines expression in cadmium chloride treated human lung cells. Environ Toxicol 30:704-11
Bauer, David; Mazzio, Elizabeth; Soliman, Karam Fa et al. (2014) Diallyl disulfide inhibits TNF?-induced CCL2 release by MDA-MB-231 cells. Anticancer Res 34:2763-70
Green, Jennifer E; Cooperwood, John S; Taka, Equar et al. (2014) Comparative proteomic analysis reveals growth inhibition by 3-N-alkyloxyestradiol derivative (SERM) in prostate cancer cells. Cancer Genomics Proteomics 11:195-200
Patel, Apurva R; Lim, Ed; Francis, Kevin P et al. (2014) Opening up the optical imaging window using nano-luciferin. Pharm Res 31:3073-84
Mazzio, E; Badisa, R; Mack, N et al. (2014) High throughput screening of natural products for anti-mitotic effects in MDA-MB-231 human breast carcinoma cells. Phytother Res 28:856-67
Badisa, Ramesh B; Mina, David A; Latinwo, Lekan M et al. (2014) Selective anticancer activity of neurotoxin 1-methyl-4-phenylpyridinium on non-small cell lung adenocarcinoma A549 cells. Anticancer Res 34:5447-52
Agyare, Edward K; Jaruszewski, Kristen M; Curran, Geoffry L et al. (2014) Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. J Control Release 185:121-9
Gangapuram, Madhavi; Mazzio, Elizabeth; Eyunni, Suresh et al. (2014) Synthesis and biological evaluation of substituted N-[3-(1H-pyrrol-1-yl)methyl]-1,2,5,6-tetrahydropyridin-1-yl]benzamide/benzene sulfonamides as anti-inflammatory agents. Arch Pharm (Weinheim) 347:360-9
Mazzio, Elizabeth A; Soliman, Karam F A (2014) Epigenetics and nutritional environmental signals. Integr Comp Biol 54:21-30
Chougule, Mahavir B; Patel, Apurva R; Patlolla, Ram et al. (2014) Epithelial transport of noscapine across cell monolayer and influence of absorption enhancers on in vitro permeation and bioavailability: implications for intestinal absorption. J Drug Target 22:498-508

Showing the most recent 10 out of 18 publications